Complete reversal of epithelial to mesenchymal transition requires inhibition of both ZEB expression and the Rho pathway

BMC Cell Biology

Volumn 10, Issue , 2009, Pages

  Das, Shreyas ^a   Becker, Bryan N ^b   Hoffmann, F Michael ^a,b   Mertz, Janet E ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; ACTIN; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; F ACTIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHOTRANSFERASE INHIBITOR; RHO FACTOR; RHO KINASE; SHORT HAIRPIN RNA; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ZEB; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UVOMORULIN; CADHERIN; HOMEODOMAIN PROTEIN; KRUPPEL LIKE FACTOR; PROTEIN KINASE INHIBITOR; SIGNAL PEPTIDE; SNIP1 PROTEIN, MOUSE; ZEB1 PROTEIN, MOUSE;

ANIMAL CELL; ARTICLE; BREAST CELL; CELL STRUCTURE; CELL TRANSFORMATION; CONTROLLED STUDY; DRUG TARGETING; EPITHELIUM CELL; FIBROSIS; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; KIDNEY TUBULE EPITHELIUM; MESENCHYME CELL; NEOPLASM; NONHUMAN; NUCLEOTIDE SEQUENCE; ORGANOGENESIS; SIGNAL TRANSDUCTION; STRESS FIBER; UPREGULATION; ANIMAL; CELL CULTURE; CELL DIFFERENTIATION; CYTOLOGY; DOWN REGULATION; DRUG EFFECT; GENETICS; HUMAN; METABOLISM; MOUSE; MOUSE MUTANT;

ANIMALS; CADHERINS; CELL DIFFERENTIATION; CELLS, CULTURED; DOWN-REGULATION; EPITHELIAL CELLS; GENE EXPRESSION; HOMEODOMAIN PROTEINS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MICE; MICE, KNOCKOUT; PROTEIN KINASE INHIBITORS; RHO-ASSOCIATED KINASES; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 74549154452     PISSN: None     EISSN: 14712121     Source Type: Journal    
DOI: 10.1186/1471-2121-10-94     Document Type: Article

References (85)

1. Savagner P. Leaving the neighborhood: molecular mechanisms involved during epithelial-mesenchymal transition. Bioessays 2001, 23:912-23. 10.1002/bies.1132, 11598958.
2. Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 2003, 15:740-6. 10.1016/j.ceb.2003.10.006, 14644200.
3. Bedi S, Vidyasagar A, Djamali A. Epithelial-to-mesenchymal transition and chronic allograft tubulointerstitial fibrosis. Transplant Rev (Orlando) 2008, 22:1-5. 2184838, 18631853.
4. Moustakas A, Heldin CH. Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci 2007, 98:1512-20. 10.1111/j.1349-7006.2007.00550.x, 17645776.
5. Strutz F, Zeisberg M, Ziyadeh FN, Yang CQ, Kalluri R, Muller GA, Neilson EG. Role of basic fibroblast growth factor-2 in epithelial-mesenchymal transformation. Kidney Int 2002, 61:1714-28. 10.1046/j.1523-1755.2002.00333.x, 11967021.
6. Tse JC, Kalluri R. Mechanisms of metastasis: epithelial-to-mesenchymal transition and contribution of tumor microenvironment. J Cell Biochem 2007, 101:816-29. 10.1002/jcb.21215, 17243120.
7. Massagu J. TGFbeta in Cancer. Cell 2008, 134:215-30. 10.1016/j.cell.2008.07.001, 18662538.
8. Ozdamar B, Bose R, Barrios-Rodiles M, Wang HR, Zhang Y, Wrana JL. Regulation of the polarity protein Par6 by TGFbeta receptors controls epithelial cell plasticity. Science 2005, 307:1603-9. 10.1126/science.1105718, 15761148.
9. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003, 425:577-84. 10.1038/nature02006, 14534577.
10. ten Dijke P, Hill CS. New insights into TGF-beta-Smad signalling. Trends Biochem Sci 2004, 29:265-73. 10.1016/j.tibs.2004.03.008, 15130563.
11. Batlle E, Sancho E, Franci C, Dominguez D, Monfar M, Baulida J, Garcia De Herreros A. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol 2000, 2:84-9. 10.1038/35000034, 10655587.
12. Moreno-Bueno G, Cubillo E, Sarrio D, Peinado H, Rodriguez-Pinilla SM, Villa S, Bolos V, Jorda M, Fabra A, Portillo F, et al. Genetic profiling of epithelial cells expressing E-cadherin repressors reveals a distinct role for Snail, Slug, and E47 factors in epithelial-mesenchymal transition. Cancer Res 2006, 66:9543-56. 10.1158/0008-5472.CAN-06-0479, 17018611.
13. Shirakihara T, Saitoh M, Miyazono K. Differential regulation of epithelial and mesenchymal markers by deltaEF1 proteins in epithelial mesenchymal transition induced by TGF-beta. Mol Biol Cell 2007, 18:3533-44. 10.1091/mbc.E07-03-0249, 1951739, 17615296.
14. Spaderna S, Schmalhofer O, Wahlbuhl M, Dimmler A, Bauer K, Sultan A, Hlubek F, Jung A, Strand D, Eger A, et al. The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer. Cancer Res 2008, 68:537-44. 10.1158/0008-5472.CAN-07-5682, 18199550.
15. Hurt EM, Saykally JN, Anose BM, Kalli KR, Sanders MM. Expression of the ZEB1 (deltaEF1) transcription factor in human: additional insights. Mol Cell Biochem 2008, 318:89-99. 10.1007/s11010-008-9860-z, 18622689.
16. Aigner K, Descovich L, Mikula M, Sultan A, Dampier B, Bonne S, van Roy F, Mikulits W, Schreiber M, Brabletz T, et al. The transcription factor ZEB1 (deltaEF1) represses Plakophilin 3 during human cancer progression. FEBS Lett 2007, 581:1617-24. 10.1016/j.febslet.2007.03.026, 17391671.
17. Eger A, Aigner K, Sonderegger S, Dampier B, Oehler S, Schreiber M, Berx G, Cano A, Beug H, Foisner R. DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene 2005, 24:2375-85. 10.1038/sj.onc.1208429, 15674322.
18. Comijn J, Berx G, Vermassen P, Verschueren K, van Grunsven L, Bruyneel E, Mareel M, Huylebroeck D, van Roy F. The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol Cell 2001, 7:1267-78. 10.1016/S1097-2765(01)00260-X, 11430829.
19. Aigner K, Dampier B, Descovich L, Mikula M, Sultan A, Schreiber M, Mikulits W, Brabletz T, Strand D, Obrist P, et al. The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. Oncogene 2007, 26:6979-88. 10.1038/sj.onc.1210508, 17486063.
20. Liu Y, El-Naggar S, Darling DS, Higashi Y, Dean DC. Zeb1 links epithelial-mesenchymal transition and cellular senescence. Development 2008, 135:579-88. 10.1242/dev.007047, 2507753, 18192284.
21. Oft M, Akhurst RJ, Balmain A. Metastasis is driven by sequential elevation of H-ras and Smad2 levels. Nat Cell Biol 2002, 4:487-94. 10.1038/ncb807, 12105419.
22. Bhowmick NA, Zent R, Ghiassi M, McDonnell M, Moses HL. Integrin beta 1 signaling is necessary for transforming growth factor-beta activation of p38 MAPK and epithelial plasticity. J Biol Chem 2001, 276:46707-13. 10.1074/jbc.M106176200, 11590169.
23. Li Y, Yang J, Dai C, Wu C, Liu Y. Role for integrin-linked kinase in mediating tubular epithelial to mesenchymal transition and renal interstitial fibrogenesis. J Clin Invest 2003, 112:503-16. 171389, 12925691.
24. Bakin AV, Rinehart C, Tomlinson AK, Arteaga CL. p38 mitogen-activated protein kinase is required for TGFbeta-mediated fibroblastic transdifferentiation and cell migration. J Cell Sci 2002, 115:3193-206.
25. Bhowmick NA, Ghiassi M, Bakin A, Aakre M, Lundquist CA, Engel ME, Arteaga CL, Moses HL. Transforming Growth Factor-beta1 Mediates Epithelial to Mesenchymal Transdifferentiation through a RhoA-dependent Mechanism. Mol Biol Cell 2001, 12:27-36. 30565, 11160820.
26. Bakin AV, Tomlinson AK, Bhowmick NA, Moses HL, Arteaga CL. Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. J Biol Chem 2000, 275:36803-10. 10.1074/jbc.M005912200, 10969078.
27. Zavadil J, Cermak L, Soto-Nieves N, Bottinger EP. Integration of TGF-beta/Smad and Jagged1/Notch signalling in epithelial-to-mesenchymal transition. Embo J 2004, 23:1155-65. 10.1038/sj.emboj.7600069, 380966, 14976548.
28. Zhao BM, Hoffmann FM. Inhibition of transforming growth factor-beta1-induced signaling and epithelial-to-mesenchymal transition by the Smad-binding peptide aptamer Trx-SARA. Mol Biol Cell 2006, 17:3819-31. 10.1091/mbc.E05-10-0990, 1556379, 16775010.
29. Huber MA, Azoitei N, Baumann B, Grunert S, Sommer A, Pehamberger H, Kraut N, Beug H, Wirth T. NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest 2004, 114:569-81. 503772, 15314694.
30. Bose R, Wrana JL. Regulation of Par6 by extracellular signals. Curr Opin Cell Biol 2006, 18:206-12. 10.1016/j.ceb.2006.02.005, 16490351.
31. Xie L, Law BK, Chytil AM, Brown KA, Aakre ME, Moses HL. Activation of the Erk pathway is required for TGF-beta1-induced EMT in vitro. Neoplasia 2004, 6:603-10. 10.1593/neo.04241, 1531665, 15548370.
32. Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, Azmi AS, Ali S, Abbruzzese JL, Gallick GE, Sarkar FH. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res 2009, 69:2400-7. 10.1158/0008-5472.CAN-08-4312, 19276344.
33. Thuault S, Tan EJ, Peinado H, Cano A, Heldin CH, Moustakas A. HMGA2 and Smads co-regulate SNAIL1 expression during induction of epithelial-to-mesenchymal transition. J Biol Chem 2008, 283:33437-46. 10.1074/jbc.M802016200, 2662269, 18832382.
34. Grande JP, Warner GM, Walker HJ, Yusufi AN, Cheng J, Gray CE, Kopp JB, Nath KA. TGF-beta1 is an autocrine mediator of renal tubular epithelial cell growth and collagen IV production. Exp Biol Med (Maywood) 2002, 227:171-81.
35. Nat KA. Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis 1992, 20:1-17.
36. Shook D, Keller R. Mechanisms, mechanics and function of epithelial-mesenchymal transitions in early development. Mech Dev 2003, 120:1351-83. 10.1016/j.mod.2003.06.005, 14623443.
37. Meyer TN, Schwesinger C, Bush KT, Stuart RO, Rose DW, Shah MM, Vaughn DA, Steer DL, Nigam SK. Spatiotemporal regulation of morphogenetic molecules during in vitro branching of the isolated ureteric bud: toward a model of branching through budding in the developing kidney. Dev Biol 2004, 275:44-67. 10.1016/j.ydbio.2004.07.022, 15464572.
38. Gawlik A, Quaggin SE. Conditional gene targeting in the kidney. Curr Mol Med 2005, 5:527-36. 10.2174/1566524054553522, 16101481.
39. Zeisberg M, Maeshima Y, Mosterman B, Kalluri R. Renal fibrosis. Extracellular matrix microenvironment regulates migratory behavior of activated tubular epithelial cells. Am J Pathol 2002, 160:2001-8. 1850832, 12057905.
40. Nishimura G, Manabe I, Tsushima K, Fujiu K, Oishi Y, Imai Y, Maemura K, Miyagishi M, Higashi Y, Kondoh H, et al. DeltaEF1 mediates TGF-beta signaling in vascular smooth muscle cell differentiation. Dev Cell 2006, 11:93-104. 10.1016/j.devcel.2006.05.011, 16824956.
41. VanSaun MN, Matrisian LM. Matrix metalloproteinases and cellular motility in development and disease. Birth Defects Res C Embryo Today 2006, 78:69-79. 10.1002/bdrc.20061, 16622849.
42. Brown K, Bhowmick NA. Linking TGF-beta-mediated Cdc25A inhibition and cytoskeletal regulation through RhoA/p160(ROCK) signaling. Cell Cycle 2004, 3:408-10.
43. Valcourt U, Kowanetz M, Niimi H, Heldin CH, Moustakas A. TGF-beta and the Smad signaling pathway support transcriptomic reprogramming during epithelial-mesenchymal cell transition. Mol Biol Cell 2005, 16:1987-2002. 10.1091/mbc.E04-08-0658, 1073677, 15689496.
44. Halder SK, Beauchamp RD, Datta PK. A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers. Neoplasia 2005, 7:509-21. 10.1593/neo.04640, 1501161, 15967103.
45. Inman GJ, Nicolas FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, Laping NJ, Hill CS. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 2002, 62:65-74. 10.1124/mol.62.1.65, 12065756.
46. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000, 351:95-105. 10.1042/0264-6021:3510095, 1221339, 10998351.
47. Lund LR, Riccio A, Andreasen PA, Nielsen LS, Kristensen P, Laiho M, Saksela O, Blasi F, Dano K. Transforming growth factor-beta is a strong and fast acting positive regulator of the level of type-1 plasminogen activator inhibitor mRNA in WI-38 human lung fibroblasts. Embo J 1987, 6:1281-6. 553930, 3111844.
48. Laping NJ, Grygielko E, Mathur A, Butter S, Bomberger J, Tweed C, Martin W, Fornwald J, Lehr R, Harling J, et al. Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542. Mol Pharmacol 2002, 62:58-64. 10.1124/mol.62.1.58, 12065755.
49. Postigo AA, Dean DC. Differential expression and function of members of the zfh-1 family of zinc finger/homeodomain repressors. Proc Natl Acad Sci USA 2000, 97:6391-6. 10.1073/pnas.97.12.6391, 18613, 10841546.
50. Bracken CP, Gregory PA, Kolesnikoff N, Bert AG, Wang J, Shannon MF, Goodall GJ. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res 2008, 68:7846-54. 10.1158/0008-5472.CAN-08-1942, 18829540.
51. Vandewalle C, Van Roy F, Berx G. The role of the ZEB family of transcription factors in development and disease. Cell Mol Life Sci 2009, 66:773-87. 10.1007/s00018-008-8465-8, 19011757.
52. Moreno-Bueno G, Portillo F, Cano A. Transcriptional regulation of cell polarity in EMT and cancer. Oncogene 2008, 27:6958-69. 10.1038/onc.2008.346, 19029937.
53. Fabre-Guillevin E, Malo M, Cartier-Michaud A, Peinado H, Moreno-Bueno G, Vallee B, Lawrence DA, Palacios J, Cano A, Barlovatz-Meimon G, et al. PAI-1 and functional blockade of SNAI1 in breast cancer cell migration. Breast Cancer Res 2008, 10:R100. 10.1186/bcr2203, 2656896, 19055748.
54. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?. Nat Rev Cancer 2007, 7:415-28. 10.1038/nrc2131, 17508028.
55. Korpal M, Kang Y. The emerging role of miR-200 family of microRNAs in epithelial-mesenchymal transition and cancer metastasis. RNA Biol 2008, 5:115-9.
56. Gregory PA, Bracken CP, Bert AG, Goodall GJ. MicroRNAs as regulators of epithelial-mesenchymal transition. Cell Cycle 2008, 7:3112-8.
57. Bracken CP, Gregory PA, Khew-Goodall Y, Goodall GJ. The role of microRNAs in metastasis and epithelial-mesenchymal transition. Cell Mol Life Sci 2009, 66:1682-99. 10.1007/s00018-009-8750-1, 19153653.
58. Guaita S, Puig I, Franci C, Garrido M, Dominguez D, Batlle E, Sancho E, Dedhar S, De Herreros AG, Baulida J. Snail induction of epithelial to mesenchymal transition in tumor cells is accompanied by MUC1 repression and ZEB1 expression. J Biol Chem 2002, 277:39209-16. 10.1074/jbc.M206400200, 12161443.
59. Korpal M, Lee ES, Hu G, Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008, 283:14910-4. 10.1074/jbc.C800074200, 18411277.
60. Bracken CP, Gregory PA, Khew-Goodall Y, Goodall GJ. The role of microRNAs in metastasis and epithelial-mesenchymal transition. Cell Mol Life Sci 2009, 66(10):1682-99. 10.1007/s00018-009-8750-1, 19153653.
61. Li Y, Boom TG, Kon D, Wan Z, Al S, Phili PA, Sarka FH. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 2009, 69:6704-12. 10.1158/0008-5472.CAN-09-1298, 19654291.
62. Paterson EL, Kolesnikoff N, Gregory PA, Bert AG, Khew-Goodall Y, Goodall GJ. The microRNA-200 family regulates epithelial to mesenchymal transition. Scientific World Journal 2008, 8:901-4.
63. Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008, 22:894-907. 10.1101/gad.1640608, 2279201, 18381893.
64. Schmalhofer O, Brabletz S, Brabletz T. E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev 2009, 28:151-66. 10.1007/s10555-008-9179-y, 19153669.
65. Raftopoulou M, Hall A. Cell migration: Rho GTPases lead the way. Dev Biol 2004, 265:23-32. 10.1016/j.ydbio.2003.06.003, 14697350.
66. Vardouli L, Moustakas A, Stournaras C. LIM-kinase 2 and cofilin phosphorylation mediate actin cytoskeleton reorganization induced by transforming growth factor-beta. J Biol Chem 2005, 280:11448-57. 10.1074/jbc.M402651200, 15647284.
67. Benitah SA, Valeron PF, van Aelst L, Marshall CJ, Lacal JC. Rho GTPases in human cancer: an unresolved link to upstream and downstream transcriptional regulation. Biochim Biophys Acta 2004, 1705:121-32.
68. Eger A, Stockinger A, Park J, Langkopf E, Mikula M, Gotzmann J, Mikulits W, Beug H, Foisner R. beta-Catenin and TGFbeta signalling cooperate to maintain a mesenchymal phenotype after FosER-induced epithelial to mesenchymal transition. Oncogene 2004, 23:2672-2680. 10.1038/sj.onc.1207416, 14755243.
69. Gal A, Sjoblom T, Fedorova L, Imreh S, Beug H, Moustakas A. Sustained TGF beta exposure suppresses Smad and non-Smad signalling in mammary epithelial cells, leading to EMT and inhibition of growth arrest and apoptosis. Oncogene 2008, 27:1218-30. 10.1038/sj.onc.1210741, 17724470.
70. Lacher MD, Tiirikainen MI, Saunier EF, Christian C, Anders M, Oft M, Balmain A, Akhurst RJ, Korn WM. Transforming growth factor-beta receptor inhibition enhances adenoviral infectability of carcinoma cells via up-regulation of Coxsackie and Adenovirus Receptor in conjunction with reversal of epithelial-mesenchymal transition. Cancer Res 2006, 66:1648-57. 10.1158/0008-5472.CAN-05-2328, 16452224.
71. Nicolas FJ, Hill CS. Attenuation of the TGF-beta-Smad signaling pathway in pancreatic tumor cells confers resistance to TGF-beta-induced growth arrest. Oncogene 2003, 22:3698-711. 10.1038/sj.onc.1206420, 12802277.
72. Abell AN, Granger DA, Johnson NL, Vincent-Jordan N, Dibble CF, Johnson GL. Trophoblast stem cell maintenance by fibroblast growth factor 4 requires MEKK4 activation of Jun N-terminal kinase. Mol Cell Biol 2009, 29:2748-61. 10.1128/MCB.01391-08, 2682043, 19289495.
73. Bolos V, Peinado H, Perez-Moreno MA, Fraga MF, Esteller M, Cano A. The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. J Cell Sci 2003, 116:499-511. 10.1242/jcs.00224, 12508111.
74. Wang X, Belguise K, Kersual N, Kirsch KH, Mineva ND, Galtier F, Chalbos D, Sonenshein GE. Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2. Nat Cell Biol 2007, 9:470-8. 10.1038/ncb1559, 2394707, 17369819.
75. Yingling JM, Blanchard KL, Sawyer JS. Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov 2004, 3:1011-22. 10.1038/nrd1580, 15573100.
76. Thuault S, Valcourt U, Petersen M, Manfioletti G, Heldin CH, Moustakas A. Transforming growth factor-beta employs HMGA2 to elicit epithelial-mesenchymal transition. J Cell Biol 2006, 174:175-83. 10.1083/jcb.200512110, 2064178, 16831886.
77. Haddad Y, Choi W, McConkey DJ. Delta-crystallin enhancer binding factor 1 controls the epithelial to mesenchymal transition phenotype and resistance to the epidermal growth factor receptor inhibitor erlotinib in human head and neck squamous cell carcinoma lines. Clin Cancer Res 2009, 15:532-42. 10.1158/1078-0432.CCR-08-1733, 19147758.
78. Zeisberg M, Kalluri R. Reversal of experimental renal fibrosis by BMP7 provides insights into novel therapeutic strategies for chronic kidney disease. Pediatr Nephrol 2008, 23:1395-8. 10.1007/s00467-008-0818-x, 18446379.
79. Hau P, Jachimczak P, Schlingensiepen R, Schulmeyer F, Jauch T, Steinbrecher A, Brawanski A, Proescholdt M, Schlaier J, Buchroithner J, et al. Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies. Oligonucleotides 2007, 17:201-12. 10.1089/oli.2006.0053, 17638524.
80. Fakhrai H, Mantil JC, Liu L, Nicholson GL, Murphy-Satter CS, Ruppert J, Shawler DL. Phase I clinical trial of a TGF-beta antisense-modified tumor cell vaccine in patients with advanced glioma. Cancer Gene Ther 2006, 13:1052-60. 10.1038/sj.cgt.7700975, 16826191.
81. Schreiber S, Feagan B, D'Haens G, Colombel JF, Geboes K, Yurcov M, Isakov V, Golovenko O, Bernstein CN, Ludwig D, et al. Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006, 4:325-34. 10.1016/j.cgh.2005.11.013, 16527696.
82. Tanihara H, Inatani M, Honjo M, Tokushige H, Azuma J, Araie M. Intraocular pressure-lowering effects and safety of topical administration of a selective ROCK inhibitor, SNJ-1656, in healthy volunteers. Arch Ophthalmol 2008, 126:309-15. 10.1001/archophthalmol.2007.76, 18332309.
83. Lee DY, Sugden B. The latent membrane protein 1 oncogene modifies B-cell physiology by regulating autophagy. Oncogene 2008, 27:2833-42. 10.1038/sj.onc.1210946, 18037963.
84. Ellison-Zelski SJ, Solodin NM, Alarig ET. Repression of ESR1 through actions of estrogen receptor alpha and Sin3A at the proximal promoter. Mol Cell Biol 2009, 29:4949-58. 10.1128/MCB.00383-09, 19620290.
85. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-8. 10.1006/meth.2001.1262, 11846609.